Crinecerfont enabled sustained GC dose reductions over 2 years, with nearly 70% of adults with classic CAH reaching physiologic dosing.
Oksana Hamidi, DO
Advertisement
Oksana Hamidi, DO, is an associate professor in the division of endocrinology and metabolism at the University of Texas Southwestern Medical Center.
Articles by Oksana Hamidi, DO
Hamidi reviews 2-year CAHtalyst data showing crinecerfont enabled sustained glucocorticoid reductions to physiologic range in adults with classic congenital adrenal hyperplasia.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Biologics in Asthma and COPD: Real-World Gaps, Outcomes, and Unmet Needs
2
Shared Decision-Making Guides Epinephrine Delivery Choice
3
GLP-1s in Dermatology: Emerging Evidence and Unanswered Questions
4
Dupilumab, Depemokimab, and COPD: What APPs See in Practice
5